The Metastasis Status and Tumor Burden-Associated CA125 Level Combined with the CD4/CD8 Ratio Predicts the Prognosis of Patients with Advanced Pancreatic Cancer: A New Scoring System

Publication date: Available online 29 July 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Chao Yang, He Cheng, Guopei Luo, Yu Lu, Meng Guo, Kaizhou Jin, Zhengshi Wang, Xianjun Yu, Chen Liu
BackgroundAlthough CA125 and the tumor immune response have been reported to be associated with pancreatic cancer, their prognostic value for advanced pancreatic cancer patients undergoing chemotherapy remains uncertain. We thus studied the prognostic value of the combination of the CA125 level with the CD4/CD8 ratio.MethodsAfter excluding patients who were lost to follow-up or for whom complete clinical data were missing, 369 participants were ultimately examined. Univariate and multivariate analyses were performed using the Cox hazards model, and Kaplan-Meier methods and log-rank tests were used for the comparison of survival rates.ResultsUnivariate and multivariate analyses showed that a high CA125 level and a high CD4/CD8 ratio were independent prognosis factors (CA125≥35 U/ml, Hazard Ratio (HR)=1.90, p<0.001; CD4/CD8≥1.8, HR=1.37, p=0.004). Moreover, after combining the CA125 level and CD4/CD8 ratio to form a new scoring system, the HR was substantially elevated (CA125≥35 U/ml and CD4/CD8≥1.8, score 2, HR=2.76, 95% confidence interval: 2.04 to 3.74, p<0.001).ConclusionsA new scoring system based on the combination of the CA125 level with the CD4/CD8 ratio could further predict the prognosis of patients with advanced pancreatic cancer.



http://ift.tt/2uNyydX